Flavii Therapeutics S.L. is a University of Barcelona spin-off founded in 2025, focused on developing innovative epigenetic therapies for central nervous system disorders. Its lead asset, FLAV-27, is a first-in-class selective G9a (EHMT2) inhibitor designed to target disease-driving mechanisms in neurodegenerative diseases. FLAV-27 has shown promising preclinical efficacy and safety in models of Alzheimer¿s disease, Huntington¿s disease, and neurodevelopmental disorders. The technology is patent-protected and exclusively licensed to Flavii. The company follows a B2B model focused on licensing and co-development partnerships to advance FLAV-27 towards clinical development.